JMT103
Phase 2Small molecule
JMT103 is one of 34 small molecule programs targeting Osteoporosis. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
172 competitors in Osteoporosis
#DrugCompanyPhaseTrials
1Boniva
CConrado Roberto Hoffmann Filho
Phase 3
Actonel
VVitae Pharmaceuticals Inc., an Allergan affiliate
Phase 3
One-Alpha
RochePhase 3
Depo-Provera
Eli LillyPhase 3
Tymlos
RRadius Health, Inc.
Phase 3
Ibandronic Acid
RochePhase 3
Tapentadol IR
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Effcamgcit
UUniversity of Texas Southwestern Medical Center
Phase 3
Prolia
AmgenPreclinical
Prolia
Qilu Pharmaceutical Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoporosis2 trials
Malignant Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JMT103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SShanghai JMT-Bio Inc.